Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Delta 9 CEO Talks Revenue & Product Growth in Cannabis

Featured Submission, Featured Submission
0 Comments| October 22, 2019

{{labelSign}}  Favorites
{{errorMessage}}



Rich TV speaks with John Arbuthnot, CEO of Canadian cannabis Company Delta 9 Inc. (TSX: DN, OTCQX: VRNDF, Forum) about the state of the cannabis industry and the future of some of its main products (flower, pre-rolls, topical and edibles) going forward. Later this fall, the Company is moving into the vaporizer space.

Having just released its Q2 2019 financial results, Delta 9 reported $8.9 million in top-line revenue, up from the year prior.

Delta 9 is engaged in Biotechnology and Medical Research. The Company is a licensed producer of medical marijuana and operates a production facility in Winnipeg, Manitoba. It has three categories of cannabis such as Indica, Sativa, and Hybrid.



{{labelSign}}  Favorites
{{errorMessage}}

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company